Results 11 to 20 of about 54,733 (297)
Multidrug Efflux Pumps in Bacteria and Efflux Pump Inhibitors
Postępy Mikrobiologii, 2022 Antimicrobial resistance is becoming a paramount health concern nowadays. The increasing drug resistance in microbes is due to improper medications or over usage of drugs. Bacteria develop many mechanisms to extrude the antibiotics entering the cell. The
Sreekantan Abhirami P. +3 more
doaj +2 more sources
Efflux Pump Inhibitors Against Nontuberculous Mycobacteria. [PDF]
Int J Mol Sci, 2020 Over the last years, nontuberculous mycobacteria (NTM) have emerged as important human pathogens. Infections caused by NTM are often difficult to treat due to an intrinsic multidrug resistance for the presence of a lipid-rich outer membrane, thus encouraging an urgent need for the development of new drugs for the treatment of mycobacterial infections ...
Rindi L.
europepmc +5 more sources
Inhibition of Staphylococcus pseudintermedius Efflux Pumps by Using Staphylococcus aureus NorA Efflux Pump Inhibitors. [PDF]
Antibiotics (Basel), 2023 One promising approach in treating antibiotic-resistant bacteria is to “break” resistances connected with antibacterial efflux by co-administering efflux pump inhibitors (EPIs) with antibiotics. Here, ten compounds, previously optimized to restore the susceptibility to ciprofloxacin (CIP) of norA-overexpressing Staphylococcus aureus, were evaluated for
Rampacci E +5 more
europepmc +5 more sources
Flavonoids as Inhibitors of Bacterial Efflux Pumps [PDF]
Molecules, 2021 Flavonoids are widely occurring secondary plant constituents, and are abundant in vegetable and fruit diets as well as herbal medicines. Therapeutic treatment options for bacterial infections are limited due to the spread of antimicrobial resistances.
Martin Waditzer, Franz Bucar
openaire +3 more sources
Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. [PDF]
Microbiology (Reading), 2023 The problem of antibiotic resistance among pathogenic bacteria has reached a crisis level. The treatment options against infections caused by multiple drug-resistant bacteria are shrinking gradually. The current pace of the discovery of new antibacterial entities is lagging behind the rate of development of new resistance.
Gaurav A +4 more
europepmc +3 more sources
Bacterial efflux pump inhibitors from natural sources [PDF]
Journal of Antimicrobial Chemotherapy, 2006 The rapid spread of bacteria expressing multidrug resistance (MDR) has necessitated the discovery of new antibacterials and resistance-modifying agents. Since the initial discovery of bacterial efflux pumps in the 1980s, many have been characterized in community- and hospital-acquired Gram-positive and Gram-negative pathogens, such as Staphylococcus ...
Stavri, Michael +2 more
openaire +3 more sources
Detection of tetracyclines and efflux pump inhibitors [PDF]
Antimicrobial Agents and Chemotherapy, 1993 Screening assays for the detection of tetracyclines and inhibitors of tetracycline efflux pumps are described. The tetracycline assay is based on the observation that the tetA(B) gene encoding the efflux pump of transposon Tn10 is induced by tetracycline.
D M, Rothstein +6 more
openaire +2 more sources
Repurposing bioactive aporphine alkaloids as efflux pump inhibitors [PDF]
Fitoterapia, 2019 Extrusion of drugs or drug-like compounds through bacterial efflux pumps is a serious health issue that leads to loss in drug efficacy. Combinatorial therapies of low-efficacy drugs with efflux pump inhibitors may help to restore the activities of such drugs.
Avci, Fatma Gizem +9 more
openaire +5 more sources
Molecules, 2020 Despite the development of targeted therapies in cancer, the problem of multidrug resistance (MDR) is still unsolved. Most patients with metastatic cancer die from MDR.
Henry Döring +3 more
doaj +1 more source
Social interactions in the Burkholderia cepacia complex : biofilms and quorum sensing [PDF]
, 2010 Burkholderia cepacia complex bacteria are opportunistic pathogens that cause respiratory tract infections in susceptible patients, mainly people with cystic fibrosis. There is convincing evidence that B.
Coenye, Tom
core +2 more sources